HOME >> BIOLOGY >> NEWS
Nasal antibiotic ointment reduces infection risk after surgery

In what may be the largest clinical trial to evaluate the effectiveness of antimicrobial agents in preventing surgical wound and hospital-based infections caused by Staphylococcus aureus, scientists at the University of Iowa and Johns Hopkins found that an antibiotic ointment, called mupirocin (moo-PIE-roe-sin), smeared inside the nose cut infection rates in half or better.

"Our results carry tremendous implications for reducing S. aureus surgical wound and other hospital-based infections, and for preventing illness and saving lives," says Trish Perl, M.D., associate professor of medicine, director of Hospital Epidemiology and Infection Control at Hopkins and an author of the study published in the June 13 issue of the New England Journal of Medicine.

Staphylococcus aureus is a widely distributed germ that normally resides in the nostrils of an estimated 25 to 30 percent of all hospitalized patients without causing harm. But it can contaminate surgical sites, causing severe and often deadly infections, especially in people with weakened immune systems, and contributing millions of dollars yearly to the costs of health care.

In the study, called MARS (for Mupirocin and the Risk of Staphyloccus aureus Infections), the researchers determined the rate of S. aureus surgical wound infections and other hospital-based infections in 4,030 adult patients who underwent various elective surgical procedures at the University of Iowa Hospitals and Clinics and the Veteran's Affairs Medical Center in Iowa City. Mupirocin antibiotic ointment, or a placebo, was applied to the inside of the nostrils twice daily for up to five days before surgery. Patients were followed for 30 days after surgery to determine if they acquired S. aureus infections.

While mupirocin ointment, made by GlaxoSmithKline, is highly effective at reducing the rate of S. aureus infections in patients undergoing surgery, as with any antibiotic, there is the risk of widespread r
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
12-Jun-2002


Page: 1 2

Related biology news :

1. Nasal contribution to breathing with exercise: The effect of race and gender
2. Could A Nasal Vaccine Finally Get Rid Of The Black Death?
3. Study Shows Athletes Get No Kick From Nasal Strips
4. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
5. Smart antibiotics may result from UCLA research
6. K-State researcher working to improve alternatives to equine antibiotics
7. Bacterial protein recycling factor possible key to new class of antibiotics
8. Bacteria spill their guts to aid researchers in quest for new antibiotics
9. Molecule that blocks key bacterial enzyme may lead to new antibiotics
10. Does antibiotic use contribute to allergies?
11. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nasal antibiotic ointment reduces infection risk after surgery

(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
Cached News: